Dr. Sullivan is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1800 Orleans Street
Baltimore, MD 21287Phone+1 410-955-5000Fax+1 410-955-5001
Summary
- Dr. David Sullivan is an infectious disease specialist in Baltimore, MD and is affiliated with Johns Hopkins Hospital. He received his medical degree from University of Alabama School of Medicine, trained in Medicine and Infectious Diseases at WUSTL before moving to Johns Hopkins Bloomberg School of Public Health. He has been in practice 33 years. He is experienced in Plasmodium falciparum, Babesia, and COVID-19. He has more than 200 publications and over 500 citings. In 2020, he pivoted from a mostly malaria bench researcher with limited observational human trials in Africa and Bangladesh to a COVID-19 clinical trialist. He is national PI on the successful effective early treatment of outpatient COVID-19 which prevented hospitalization with a single transfusion of high SARS-CoV-2 antibody titer convalescent plasma (NCT04373460). The Clinical Research Forum selected the work in the Top Ten published 2022 clinical research trials. He is working on a Biologic License Application for COVID-19 convalescent plasma for those immunosuppressed.
Education & Training
- Washington University/B-JH/SLCH ConsortiumFellowship, Infectious Disease, 1992 - 1997
- Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 1988 - 1991
- University of Alabama School of MedicineClass of 1988
Certifications & Licensure
- MD State Medical License 1997 - 2025
- American Board of Internal Medicine Infectious Disease
Clinical Trials
- Convalescent Plasma to Limit SARS-CoV-2 Associated Complications Start of enrollment: 2020 Jun 03
Publications & Presentations
PubMed
- 8 citationsCerebrospinal fluid Plasmodium falciparum histidine-rich protein-2 in pediatric cerebral malaria.Kiran T. Thakur, Jimmy Vareta, Kathryn A. Carson, Samuel Kampondeni, Michael J. Potchen
Malaria Journal. 2018-03-23 - 35 citationsConvalescent plasma with a high level of virus-specific antibody effectively neutralizes SARS-CoV-2 variants of concern.Maggie Li, Evan J Beck, Oliver Laeyendecker, Yolanda Eby, Aaron A R Tobian
Blood Advances. 2022-06-28 - 160 citationsEarly Outpatient Treatment for Covid-19 with Convalescent Plasma.David J Sullivan, Kelly A Gebo, Shmuel Shoham, Evan M Bloch, Bryan Lau
The New England Journal of Medicine. 2022-05-05
Journal Articles
- In Vivo Compartmental Kinetics of Plasmodium Falciparum Histidine-Rich Protein II in the Blood of Humans and in BALB/c Mice Infected with a Transgenic Plasmodium Bergh...David Sullivan, MD, BioMed Central
Press Mentions
- Early, High Doses of Plasma Can Prevent COVID HospitalizationsMarch 6th, 2023
- People with Epilepsy Live 10-12-Years Shorter Lives – Danish Cohort StudyApril 12th, 2022
- Convalescent Plasma Reduces Hospitalization Risk in COVID-19March 30th, 2022
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: